Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.

Jpn J Clin Oncol · 2026 · PMC13149310 · PMID 41789591

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Overall, there was a slight trend that survival rate was higher in patients who received T-DXd treatment ≤2/>2 months after nivolumab therapy (HR [95% CI]: 0.79 [0.53–1.17]) compared with those who received T-DXd treatment ≤3/>3 months (HR [95% CI]: 0.87 [0.58–1.30]), ≤4/>4 months (HR [95% CI]: 0.97 [0.65–1.46]), and ≤5/>5 months (HR [95% CI]: 0.93 [0.62–1.40]) after nivolumab therapy ( Fig.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.